BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

(2017) Chiun Hsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Marked for death: targeting epigenetic changes in cancer

(2017) Sophia Xiao Pfister et al.   NATURE REVIEWS DRUG DISCOVERY

A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis

(2016) Ning Li et al.   CANCER LETTERS

Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model

(2016) Xuguang Zhu et al.   CLINICAL CANCER RESEARCH

OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models

(2016) Caroline Berenguer-Daizé et al.   INTERNATIONAL JOURNAL OF CANCER

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer

(2016) Mark L. McCleland et al.   JOURNAL OF CLINICAL INVESTIGATION

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

(2016) Li Zhang et al.   LANCET

Nasopharyngeal carcinoma

(2016) Melvin L K Chua et al.   LANCET

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth

(2015) Hufeng Zhou et al.   Cell Host & Microbe

Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective

(2015) Anne W.M. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

(2015) Pierre Blanchard et al.   LANCET ONCOLOGY

MYC, Metabolism, and Cancer

(2015) Z. E. Stine et al.   Cancer Discovery

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

The genomic landscape of nasopharyngeal carcinoma

(2014) De-Chen Lin et al.   NATURE GENETICS

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy

(2013) M. F. Segura et al.   CANCER RESEARCH

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer

(2013) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

(2013) Z. Cheng et al.   CLINICAL CANCER RESEARCH

The future of epigenetic therapy in solid tumours—lessons from the past

(2013) Nilofer Azad et al.   Nature Reviews Clinical Oncology

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

(2012) C. J. Ott et al.   BLOOD

Epigenetic protein families: a new frontier for drug discovery

(2012) Cheryl H. Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

(2012) W. W. Lockwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

(2011) Mark A. Dawson et al.   NATURE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Epigenetic modifications and human disease

(2010) Anna Portela et al.   NATURE BIOTECHNOLOGY